NASDAQ:ALBO Albireo Pharma - ALBO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Albireo Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $44.07 +0.12 (+0.27%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$43.82▼$44.0850-Day Range$18.01▼$44.1052-Week Range$16.02▼$44.40Volume846,186 shsAverage Volume719,190 shsMarket Capitalization$912.25 millionP/E RatioN/ADividend YieldN/APrice Target$48.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Albireo Pharma MarketRank™ ForecastAnalyst RatingHold2.14 Rating ScoreUpside/Downside8.9% Upside$48.00 Price TargetShort InterestHealthy3.98% of Shares Sold ShortDividend StrengthN/ASustainability-1.69Upright™ Environmental ScoreNews Sentiment0.36Based on 7 Articles This WeekInsider TradingSelling Shares$178,670 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($7.86) to ($6.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.15 out of 5 starsMedical Sector492nd out of 1,055 stocksPharmaceutical Preparations Industry239th out of 519 stocks 2.1 Analyst's Opinion Consensus RatingAlbireo Pharma has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 1 buy rating, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $48.00, Albireo Pharma has a forecasted upside of 8.9% from its current price of $44.07.Amount of Analyst CoverageAlbireo Pharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.98% of the outstanding shares of Albireo Pharma have been sold short.Short Interest Ratio / Days to CoverAlbireo Pharma has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Albireo Pharma has recently decreased by 16.75%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlbireo Pharma does not currently pay a dividend.Dividend GrowthAlbireo Pharma does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlbireo Pharma has received a 59.81% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Liver-disease medication (A05)", "Clinical research services for physiological diseases ", and "Constipation medication (A06)" products. See details.Environmental SustainabilityThe Environmental Impact score for Albireo Pharma is -1.69. Previous Next 2.4 News and Social Media Coverage News SentimentAlbireo Pharma has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Albireo Pharma this week, compared to 2 articles on an average week.MarketBeat Follows5 people have added Albireo Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Albireo Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $178,670.00 in company stock.Percentage Held by InsidersOnly 6.90% of the stock of Albireo Pharma is held by insiders.Percentage Held by Institutions94.25% of the stock of Albireo Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Albireo Pharma are expected to grow in the coming year, from ($7.86) to ($6.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Albireo Pharma is -6.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Albireo Pharma is -6.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlbireo Pharma has a P/B Ratio of 4.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Albireo Pharma (NASDAQ:ALBO) StockAlbireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.Read More Receive ALBO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Albireo Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ALBO Stock News HeadlinesJanuary 25, 2023 | americanbankingnews.comInsider Selling: Albireo Pharma, Inc. (NASDAQ:ALBO) CEO Sells 1,057 Shares of StockJanuary 24, 2023 | reuters.comALBO.PH - | Stock Price & Latest News | ReutersJanuary 28, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 22, 2023 | americanbankingnews.comAlbireo Pharma, Inc. (NASDAQ:ALBO) Short Interest UpdateJanuary 21, 2023 | finance.yahoo.comWhy These Two Biotech Stocks Blasted Higher This WeekJanuary 21, 2023 | americanbankingnews.comMartha J. Carter Sells 938 Shares of Albireo Pharma, Inc. (NASDAQ:ALBO) StockJanuary 21, 2023 | americanbankingnews.comAlbireo Pharma, Inc. (NASDAQ:ALBO) CFO Simon N.R. Harford Sells 1,776 Shares of StockJanuary 11, 2023 | msn.comCowen & Co. Downgrades Albireo Pharma: Here's What You Need To KnowJanuary 28, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 11, 2023 | msn.comAnalysts move to downgrade Albireo Pharma after Ipsen's proposed acquisitionJanuary 11, 2023 | nasdaq.comAlbireo Pharma Spikes On Agreement To Be Acquired By IpsenJanuary 11, 2023 | markets.businessinsider.comExpert Ratings for Albireo PharmaJanuary 9, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether Albireo Pharma, Inc. has obtained a Fair Price in its transaction with IpsenJanuary 9, 2023 | technews.tmcnet.comALBO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Albireo Pharma, Inc. Is Fair to ShareholdersJanuary 9, 2023 | finance.yahoo.comFrance-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, PipelineJanuary 2, 2023 | seekingalpha.comAlbireo: Slowly Capturing Some Of The Liver Disease MarketDecember 21, 2022 | finance.yahoo.comWe're Not Very Worried About Albireo Pharma's (NASDAQ:ALBO) Cash Burn RateDecember 6, 2022 | finance.yahoo.comAlbireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., to Board of DirectorsNovember 30, 2022 | finance.yahoo.comReimbursed Access to Bylvay® (odevixibat) Approved in France for Patients with PFIC 1 & 2November 10, 2022 | finance.yahoo.comAlbireo Pharma (NASDAQ:ALBO) dips 16% this week as increasing losses might not be inspiring confidence among its investorsNovember 9, 2022 | finance.yahoo.comAlbireo to Participate in Jefferies London Healthcare ConferenceNovember 9, 2022 | seekingalpha.comAlbireo Pharma, Inc. (ALBO) Q3 2022 Earnings Call TranscriptNovember 8, 2022 | finance.yahoo.comAlbireo Reports Q3 2022 Financial Results and Business UpdateNovember 8, 2022 | finance.yahoo.comAlbireo Pharma (ALBO) Reports Q3 Loss, Tops Revenue EstimatesNovember 7, 2022 | finance.yahoo.comBylvay® (odevixibat) Data Presented at AASLD The Liver Meeting® 2022, Demonstrating Native Liver Survival in Children Across PFIC TypesNovember 3, 2022 | finance.yahoo.comAlbireo Announces 2022 SPARK Grant WinnersNovember 2, 2022 | finance.yahoo.comAlbireo Completes Phase 3 BOLD Study Enrollment of Bylvay(R) in Biliary AtresiaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ALBO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Albireo Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ALBO Company Calendar Last Earnings11/08/2022Today1/28/2023Next Earnings (Estimated)3/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALBO CUSIPN/A CIK1322505 Webwww.albireopharma.com Phone(857) 254-5555Fax203-796-5001Employees130Year Founded2003Price Target and Rating Average Stock Price Forecast$48.00 High Stock Price Forecast$59.00 Low Stock Price Forecast$42.00 Forecasted Upside/Downside+8.9%Consensus RatingHold Rating Score (0-4)2.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($6.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-34,030,000.00 Net Margins-228.51% Pretax Margin-235.11% Return on Equity-97.13% Return on Assets-46.89% Debt Debt-to-Equity RatioN/A Current Ratio6.32 Quick Ratio6.23 Sales & Book Value Annual Sales$40.58 million Price / Sales22.48 Cash FlowN/A Price / Cash FlowN/A Book Value$9.11 per share Price / Book4.84Miscellaneous Outstanding Shares20,700,000Free Float19,273,000Market Cap$912.25 million OptionableOptionable Beta0.81 Social Links Key ExecutivesMr. Ronald H. W. Cooper (Age 60)CEO, Pres & Director Comp: $1.1MMr. Simon Nicolas Reade Harford (Age 62)CFO & Treasurer Comp: $687.78kMs. Martha J. Carter (Age 71)Chief Regulatory Officer Comp: $710.69kDr. Per-Goran Gillberg Ph.D.Co-Founder & VP of Devel.Dr. Jan P. Mattsson Ph.D. (Age 59)Chief Scientific Officer, MD (Sweden) & Co-Founder Ms. Joan ConnollyChief Technology OfficerMr. Jason G. Duncan (Age 49)Chief Legal Officer, Gen. Counsel & Sec. Ms. Michelle Graham (Age 56)Chief HR Officer Dr. Kristina TorfgardVP & Global Project HeadMs. Pamela Stephenson M.P.H. (Age 55)Chief Commercial Officer More ExecutivesKey CompetitorsJanux TherapeuticsNASDAQ:JANXPharming GroupNASDAQ:PHARPureTech HealthNASDAQ:PRTCAmryt PharmaNASDAQ:AMYTBioXcel TherapeuticsNASDAQ:BTAIView All CompetitorsInsiders & InstitutionsRice Hall James & Associates LLCBought 9,387 shares on 1/27/2023Ownership: 2.481%Ronald Harold Wilfred CooperSold 1,057 sharesTotal: $46,296.60 ($43.80/share)Pamela StephensonSold 102 sharesTotal: $4,467.60 ($43.80/share)Chicago Capital LLCBought 242,710 shares on 1/20/2023Ownership: 6.582%Simon N.R. HarfordSold 1,776 sharesTotal: $77,788.80 ($43.80/share)View All Insider TransactionsView All Institutional Transactions ALBO Stock - Frequently Asked Questions Should I buy or sell Albireo Pharma stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last twelve months. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ALBO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALBO, but not buy additional shares or sell existing shares. View ALBO analyst ratings or view top-rated stocks. What is Albireo Pharma's stock price forecast for 2023? 7 equities research analysts have issued twelve-month target prices for Albireo Pharma's stock. Their ALBO share price forecasts range from $42.00 to $59.00. On average, they anticipate the company's share price to reach $48.00 in the next year. This suggests a possible upside of 8.9% from the stock's current price. View analysts price targets for ALBO or view top-rated stocks among Wall Street analysts. How have ALBO shares performed in 2023? Albireo Pharma's stock was trading at $21.61 at the start of the year. Since then, ALBO shares have increased by 103.9% and is now trading at $44.07. View the best growth stocks for 2023 here. When is Albireo Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023. View our ALBO earnings forecast. How were Albireo Pharma's earnings last quarter? Albireo Pharma, Inc. (NASDAQ:ALBO) issued its quarterly earnings data on Tuesday, November, 8th. The biopharmaceutical company reported ($1.89) EPS for the quarter, missing analysts' consensus estimates of ($1.86) by $0.03. The biopharmaceutical company had revenue of $9.83 million for the quarter, compared to the consensus estimate of $9.68 million. Albireo Pharma had a negative net margin of 228.51% and a negative trailing twelve-month return on equity of 97.13%. What other stocks do shareholders of Albireo Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer (ET), Heat Biologics (HTBX), Amarin (AMRN), Exelixis (EXEL), Palatin Technologies (PTN), GW Pharmaceuticals (GWPH), Viking Therapeutics (VKTX), Agenus (AGEN), OPKO Health (OPK) and Pfizer (PFE). What is Albireo Pharma's stock symbol? Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO." Who are Albireo Pharma's major shareholders? Albireo Pharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Chicago Capital LLC (6.58%) and Rice Hall James & Associates LLC (2.48%). Insiders that own company stock include Jan Mattsson, Jason Duncan, Life Sciences Maste Perceptive, Martha J Carter, Pamela Stephenson, Patrick Taylor Horn, Perceptive Advisors Llc, Ronald Harold Wilfred Cooper and Simon NR Harford. View institutional ownership trends. How do I buy shares of Albireo Pharma? Shares of ALBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Albireo Pharma's stock price today? One share of ALBO stock can currently be purchased for approximately $44.07. How much money does Albireo Pharma make? Albireo Pharma (NASDAQ:ALBO) has a market capitalization of $912.29 million and generates $40.58 million in revenue each year. The biopharmaceutical company earns $-34,030,000.00 in net income (profit) each year or ($6.72) on an earnings per share basis. How many employees does Albireo Pharma have? The company employs 130 workers across the globe. How can I contact Albireo Pharma? Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The official website for the company is www.albireopharma.com. The biopharmaceutical company can be reached via phone at (857) 254-5555, via email at shareholders@biodel.com, or via fax at 203-796-5001. This page (NASDAQ:ALBO) was last updated on 1/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.